Global Scans · Sclerosis · Weekly Summary

• In the field of healthcare, BCI has demonstrated significant potential for replacing or restoring functions damaged by neurological conditions, such as amyotrophic lateral sclerosis, cerebral palsy, stroke, and spinal cord injuries. PubMed Central (PMC)
• The Department of Defense has anticipated funding opportunities in fiscal year 2025 for research involving Tuberous Sclerosis Complex, vision, and ovarian cancer. Research & Engagement
• Vaccines might one day make multiple sclerosis become a historical disease like polio. Science News
• Products extracted from cannabis will be sold in Spanish pharmacies in order to help alleviate symptoms associated with diseases such as multiple sclerosis, some forms of epilepsy, the side effects of chemotherapy, cancer, chronic pain and endometriosis. The Local
• Another key phase 3 readout Roche expects in 2026 is FENhance 1, the second for fenebrutinib in relapsing multiple sclerosis. Fierce Pharma
• Biogen and its investors also need an aducanumab approval after the company recently lost a patent fight over its big-selling multiple sclerosis drug Tecfidera: If approved, annual sales are forecast to reach $5.3 billion by 2025. U.S.
• Sales are expected to fall in 2026 after growing 2% last year, driven largely by multiple sclerosis drugs losing exclusivity in Europe and facing new competition in the US. The Edge Malaysia
• Biogen is betting that growth from newer drugs - including Alzheimer's treatment Leqembi and rare-disease drugs Skyclarys and Spinraza - will offset its declining multiple sclerosis medicines as competition from generics erode sales. The Edge Malaysia
• The FDA has cleared the initiation of a pivotal, 500-patient, randomized, placebo-controlled phase 3 trial dubbed PREVAiLS, which will assess the efficacy and safety of pridopidine in patients with early-stage, rapidly progressive amyotrophic lateral sclerosis. NeurologyLive - Clinical Neurology News and Neurology E

Last updated: 21 September 2026